



*Partnering for the Future*



---

**105 Panel: Addressing the Opioid  
Crisis: Pain Management, Addiction  
Treatment, and Recovery in the  
Context of APMs**

OCTOBER 22, 2018

SHERATON TYSONS HOTEL

TYSONS, VA

# Welcome



## **Bill Hazel**

*Former Secretary, Health and  
Human Resources,  
Commonwealth of Virginia*

Partnering for the Future

# Panel Speakers



**Mary  
Applegate**

*Medical Director,  
Ohio Department  
of Medicaid*



**Martin  
Rosenzweig**

*Senior Behavioral  
Medical Director,  
Optum*



**Andrey  
Ostrovsky**

*CEO, Concerted  
Care Group*



**J. Alice  
Thompson**

*Social Science  
Researcher, Center for  
Medicare and Medicaid  
Innovation*



*Partnering for the Future*



---

# Three Ways APMs Can Help Combat the Opioid Epidemic

OCTOBER 22, 2018

SHERATON TYSONS HOTEL

TYSONS, VA

# Welcome



## **Mary S. Applegate, MD, FAAP, FACP**

*Medicaid Medical Director  
Ohio Department of Medicaid*

Partnering for the Future

# Ohio's goal: 80-90% in APMs within 5 years

## Progress to date

### Comprehensive Primary Care (CPCs)

- 1M+ patients
- 145 CPC practices
- ~10,000 primary care practitioners

### Episodes

- 1M+ patients
- 43 episodes
- 13,000+ providers (PAPs)

### Behavioral Health Care Coord. (BHCCs)

*In design: delegating care coordination to qualified BH entities*

# 3 ways APMs can address the opioid epidemic


- I **Metrics:** include opioids-related quality metrics linked to payment
- II **Reporting:** increase transparency and provide actionable insights
- III **Predictive Analytics:** for earlier identification and intervention



# Safer opioid prescriptions tied to incentives



Variation  
in new  
opioid  
prescrip-  
tion  
(fill)  
rate



Source: Ohio claims data. Episodes ending in 2014



# I Include OUD care metrics in APMs

## Examples of OUD care metrics under consideration

- % members with OUD not receiving any treatment
- Opioid-related ED / IP visits per 1,000 member months
- % patients receiving > 80mg MED
- % members with # urine drug screens per month while receiving MAT
- % members not screened for Hepatitis B or C



# Hospital-level change through APMs: Care Innovation and Community Improvement Program (CICIP)

- Additional upside payment to hospitals through managed care plans
- Conditional to specific opioid-related quality metrics
- To align quality improvement strategies



## Examples of CICIP measures:

- % patients on opioids AND benzodiazepine
- % patients receiving > 80mg MED
- Follow-up after inpatient mental health stay
- Improvement of maternity measures
- ED utilization reduction

# Reporting for Insight and Action

- Rx
- Inpatient
- ED
- Outpatient

Patient journey dashboard



Care gap

# II Reporting for Insight and Action

Referral reports may drive improved quality and costs of care

## ASTHMA EXACERBATION – REFERRAL REPORT


Provider (PAP)	Risk-adj. cost	Meets quality standards	# of episodes from your patients	% of your episodes
Provider 1	\$	✓	18	15%
Provider 2	\$\$	✗	15	13%
Provider 3	\$\$\$\$	✓	11	9%

# III Predictive modeling: population health insights

OID risk  
in your  
panel

% of  
members


- Level 1 - Little or no risk for OUD
- Level 2 - Moderate risk for OUD
- Level 3 - High risk for OUD
- Level 4 - Diagnosed with OUD



# III Predictive modeling: population health insights


Risk factor prevalence in OUD-diagnosed population % members

## High-risk factors



SDoH risk factors

## Moderate-risk factors



# Additional Considerations

## Prevention

- **School-based health** incentives for CPCs
- Further leverage & evolve **predictive modelling**
- Link opioids-specific metrics to payment in **more episodes, CPC**, aligning with PDMP
- Opportunities with 100% **e-prescribing**
- Expand models to **include pain management** avoid unintended consequences for chronic pain patients

## Treatment

- Link payment to **retention in care** (referrals, pain management)
- Further leverage CPC with long-acting MATs
- HCC program to refer to highest **quality OUD treatment providers**

*Partnering for the Future*



# Implementing Evidence-based Addiction Treatment in the Context of Upstream Barriers to Health

**Andrey Ostrovsky MD** | *CEO* | *Concerted Care Group* | *@andreyostrovsky*



# Welcome



## **Andrey Ostrovsky**

*CEO, Concerted  
Care Group*

Partnering for the Future

# Faculty Disclosure

Andrey Ostrovsky, MD



Social Innovation Ventures

Source: [socialinnovationventures.co](http://socialinnovationventures.co)

Partnering for the Future

# Catharsis at the front line

- **Vision:** Eliminate addiction in all American communities
- **Mission:** Empower every individual with the ability to improve the quality of their life through comprehensive, integrated, and evidence-based addiction treatment.
- **True North Goals:**
  - Improve clinical outcomes
  - Become financially sustainable
  - Increase joy at work



# 4 pillars of MAT

- Medication (methadone, buprenorphine, or naltrexone)
- Primary care
- Addictions counseling and mental health therapy
- Social supports

Source: <https://www.samhsa.gov/medication-assisted-treatment/treatment>

*Partnering for the Future*

# OTP vs OBOT

- Opioid Treatment Program (OTP)
  - SAMHSA-licensed via CARF or Joint Commission to administer methadone for opioid use disorder
  - Can administer methadone, buprenorphine and naltrexone as well
  - Sometimes referred to as “methadone clinic”
- OBOT (Office-based Outpatient Treatment)
  - Individual providers need to have a DATA 2000 waiver
  - Can administer buprenorphine and naltrexone, but not methadone

Source: <https://www.samhsa.gov/medication-assisted-treatment/treatment>

# Dispelling Myths about MAT




## **MAT JUST TRADES ONE ADDICTION FOR ANOTHER:**

MAT bridges the biological and behavioral components of addiction. Research indicates that a combination of medication and behavioral therapies can successfully treat SUDs and help sustain recovery. (10)



## **MAT IS ONLY FOR THE SHORT TERM:**

Research shows that patients on MAT for at least 1-2 years have the greatest rates of long-term success. There is currently no evidence to support benefits from stopping MAT. (11)



## **MY PATIENT'S CONDITION IS NOT SEVERE ENOUGH TO REQUIRE MAT:**

MAT utilizes a multitude of different medication options (agonists, partial agonists and antagonists) that can be tailored to fit the unique needs of the patient (2).

Source: TheNationalCouncil.org

Partnering for the Future

# Dispelling Myths about MAT



## **MAT INCREASES THE RISK FOR OVERDOSE IN PATIENTS:**

MAT helps to prevent overdoses from occurring. Even a single use of opioids after detoxification can result in a life-threatening or fatal overdose. Following detoxification, tolerance to the euphoria brought on by opioid use remains higher than tolerance to respiratory depression. (14)



## **PROVIDING MAT WILL ONLY DISRUPT AND HINDER A PATIENT'S RECOVERY PROCESS:**

MAT has been shown to assist patients in recovery by improving quality of life, level of functioning and the ability to handle stress. Above all, MAT helps reduce mortality while patients begin recovery.

$$l \leq \frac{l_1 l_2}{k}; k = \frac{4}{\sqrt{4EJ}};$$

## **THERE ISN'T ANY PROOF THAT MAT IS BETTER THAN ABSTINENCE:**

MAT is evidence-based and is the recommended course of treatment for opioid addiction. American Academy of Addiction Psychiatry, American Medical Association, The National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, National Institute on Alcohol Abuse and Alcoholism, Centers for Disease Control and

Source: TheNationalCouncil.org

Partnering for the Future

# Dispelling Myths about MAT



## **MOST INSURANCE PLANS DON'T COVER MAT:** As of


May 2013, 31 state Medicaid FFS programs covered methadone maintenance treatment provided in outpatient programs (4). State Medicaid agencies vary as to whether buprenorphine is listed on the Preferred Drug List (PDL), and whether prior authorization is required (a distinction often made based on the specific buprenorphine medication type). Extended-release naltrexone is listed on the Medicaid PDL in over 60 percent of states. (5)

Source: TheNationalCouncil.org

Partnering for the Future




# Role of Non-Healthcare Determinants



Source: Schroeder. NEJM. 2007. Adapted from McGinnis et al.


Partnering for the Future

# Role of Social Determinants of Health



Source: Braverman P et al. Broadening the Focus: The Need to Address the Social Determinants of Health. AJPM. 2011. 40(1):1.

# Role of Social Determinants of Health



Source: Braverman P et al. Broadening the Focus: The Need to Address the Social Determinants of Health. AJPM. 2011. 40(1):1.

# Role of Social Determinants of Health



Partnering for the Future

# Pathways to OUD

- Pathway 1: Inadequately controlled chronic physical pain leads to misuse (17%)
- Pathway 2: Some individuals are vulnerable to opioid dependence even after brief opioid exposure (12%)
- Pathway 3: Prior substance use problems and introduction of prescribed opioids (15%)
- Pathway 4: Relief from emotional distress reinforces misuse or abuse (21%)
- Pathway 5: Recreational initiation or non-medically supervised use of opioids (40%)

Source: Stumbo et al. Patient-reported PATHWAYS to opioid use disorders and pain-related barriers to treatment engagement. *Journal of Substance Abuse Treatment* 73 (2017) 47–54.

Partnering for the Future

# “Gas and go” vs Comprehensive care vs “Abstinence”





Fig. 1. Percent urine tests positive for opiates by assessment month and treatment condition. (◆, 21-day methadone detoxification; ■, 6-month methadone maintenance with minimal counseling; ▲, 6-month methadone maintenance with standard counseling) Although the standard errors of some of the proportions may overlap [ $SEP = p(1 - p)/n$ ], the combined difference was statistically significant. Opiate positive urine tests months 1–6: Minimal MM vs. Detox  $p = .0302$ . Opiate positive urine tests months 1–8.5: Minimal MM vs. Detox  $p = .0149$ .

Source: Gruber et al. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. *Drug and Alcohol Dependence*. April 1, 2008. Volume 94, Issues 1-3, Pages 199–206.


# “Gas and go” vs Comprehensive care vs “Abstinence”



Source: Kakko et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet* 361 (9358). 2003. P662-668.

Partnering for the Future

# “Gas and go” vs Comprehensive care vs “Abstinence”



**4 out of 20 people died in the placebo arm versus none in the buprenorphine group (p = 0.015)**

Source: Kakko et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet* 361 (9358). 2003. P662-668.



# Care needs to be individualized


Opinion

## Addiction Doesn't Always Last a Lifetime

In fact, most people recover, often on their own. Here are some of their stories.




Source: Szalavitz M. NYT. Aug 2018.

# How to manage patients not adhering to treatment



A stepped care approach to the delivery of health care services. From *Addictive Behaviors Across the Lifespan: Prevention, Treatment, and Policy Issues* (p. 150), by J. S. Baer, G. A. Marlatt, & R. J. McMahon (Eds.), 1993, Beverly Hills, CA: Sage. Copyright 1993 by M. B. Sobell and L. C. Sobell. Adapted with permission.


# How to manage patients not adhering to treatment

Phases of Recovery	Criteria	Treatment
<b>Orange Phase:</b> Induction Phase / or IOP	First 4 weeks Assessment / getting to know each other	<ul style="list-style-type: none"> <li>• 1 counseling session per week</li> <li>• 1 group per week – to include Orientation group &amp; overdose prevention group</li> <li>• 2 MD/NP meetings</li> <li>• Weekly urinalysis</li> </ul>
 <i>(Step Up! Step Down! With changing needs)</i>		
<b>Yellow Phase:</b> Intensive Phase	Current struggle with maintaining abstinence	<ul style="list-style-type: none"> <li>• 1 counseling session per week</li> <li>• 2 groups per week</li> <li>• 2 MD/NP meetings per month</li> <li>• Weekly urinalysis</li> </ul>
		
<b>Green Phase:</b> Moderate Phase	Some use may continue now & then. Earning some take homes or working towards earning take homes, moderately engaged in treatment.	<ul style="list-style-type: none"> <li>• 2 counseling sessions per month</li> <li>• 1 group per week</li> <li>• 1 MD/NP meetings per month</li> <li>• Monthly urinalysis</li> </ul>
		
<b>Blue Phase:</b> Maintenance Phase	Abstinence from all substances maintained. Receiving take homes.	<ul style="list-style-type: none"> <li>• 1 60 minute counseling session per month</li> <li>• 1 MD/NP visit every 3 months</li> <li>• Monthly urinalysis</li> </ul>




<b>Red Phase:</b> Harm Reduction	Non-adherence to treatment plan	<ul style="list-style-type: none"> <li>• Non-preferential dosing times</li> <li>• Weekly urinalysis</li> </ul>
-------------------------------------	---------------------------------	--

# How to manage patients not adhering to treatment



**Figure 3.** Time to relapse during 9 months of follow-up; vocational rehabilitation (VR) only versus VR plus contingency management (CM). Note: Sobriety incentives were available weeks 1–16 only.



**Figure 1.** Vocational rehabilitation (VR) only versus VR plus contingency management (CM) during 36 weeks of follow-up ( $n = 100$ , 50 each group): (a) time to competitive employment (CE) and (b) percentage engaged in CE.

Source: Drebing CE et al. Adding contingency management intervention to vocational rehabilitation: Outcomes for dually diagnosed veterans. JRRD. 2007. 44(6)



*Partnering for the Future*



---

# CMS Innovation Center Opioid Strategy and Current Efforts

J. Alice Thompson

Center for Medicare & Medicaid Innovation (CMMI)

Centers for Medicare & Medicaid Services (CMS)

# Welcome



## **J. Alice Thompson**

*Social Science Researcher, Center for  
Medicare and Medicaid Innovation*

Partnering for the Future

# The CMS Innovation Center Statute

“The purpose of the [Center] is to test innovative payment and service delivery models to reduce program expenditures...while preserving or enhancing the quality of care furnished to individuals under such titles.”

## Three scenarios for success from Statute:

1. **Quality improves; cost neutral**
2. **Quality neutral; cost reduced**
3. **Quality improves; cost reduced (best case)**

If a model meets one of these three criteria and other statutory prerequisites, the statute allows the Secretary to expand the duration and scope of a model through rulemaking.

# CMS Value-Based Payment Framework



## Category 1

Fee for Service –  
No Link to  
Quality & Value



## Category 2

Fee for Service –  
Link to  
Quality & Value



## Category 3

APMs Built on  
Fee-for-Service  
Architecture



## Category 4




Population-Based  
Payment

<https://hcp-lan.org/workproducts/apm-whitepaper.pdf>

Partnering for the Future



# CMS Roadmap to Address the Opioid Crisis

 <h2>PREVENTION</h2> <p>Significant progress has been made in identifying overprescribing patterns</p> <ol style="list-style-type: none"><li>1. <b>Identify</b> and stop overprescribing of opioids</li><li>2. <b>Enhance</b> diagnosis of OUD to get people the support they need earlier</li><li>3. <b>Promote</b> effective, non-opioid pain treatments</li></ol>	 <h2>TREATMENT</h2> <p>Medicare, Medicaid, and private health plans provide some coverage for pain and opioid use disorder treatments</p> <ol style="list-style-type: none"><li>1. <b>Ensure</b> access to treatment across CMS programs and geography</li><li>2. <b>Give</b> patients choices for a broader range of treatments</li><li>3. <b>Support</b> innovation through new models and best practices</li></ol>	 <h2>DATA</h2> <p>Data provides insight into doctor, pharmacy, and patient use of prescription opioids and effectiveness of treatment</p> <ol style="list-style-type: none"><li>1. <b>Understand</b> opioid use patterns across populations</li><li>2. <b>Promote</b> sharing of actionable data across continuum of care</li><li>3. <b>Monitor</b> trends to assess impact of prevention and treatment solutions</li></ol>
---	--	--

<https://www.cms.gov/About-CMS/Agency-Information/Emergency/Downloads/Opioid-epidemic-roadmap.pdf>


# Integrated Care for Kids (InCK) Model

The **Integrated Care for Kids (InCK) Model** is a child-centered *local service delivery* and *state payment model* aimed at **reducing expenditures** and **improving the quality of care** for children covered by Medicaid and CHIP, especially those with or at-risk for developing significant health needs.

**Up to 8 cooperative agreement awards anticipated Summer 2019**


## Goals:

- 1** Improving performance on priority measures of child health
- 2** Reducing avoidable inpatient stays and out-of-home placements
- 3** Creation of sustainable Alternative Payment Models (APMs)



# Visit the LAN Website for our Resources

<https://hcp-lan.org/>




Partnering for the Future

# Exit Survey

We want to know what you think!

---

Please take a moment to complete the exit survey so we can continue to improve and enrich the LAN. Use the link in *Guidebook* for this session to provide us your feedback.



# Contact Us

We want to hear from you!



[www.hcp-lan.org](http://www.hcp-lan.org)



[@Payment\\_Network](https://twitter.com/Payment_Network)



[PaymentNetwork@mitre.org](mailto:PaymentNetwork@mitre.org)



Search: Health Care Payment  
Learning and Action Network





*Partnering for the Future*

 **LAN SUMMIT**  
Health Care Payment Learning & Action Network

---

**Thank You!**